IL6 and Parkinson disease: However, increased levels of miR-675-5p before NM-Sal treatment has reduced IL-6 (P = 0.0036, Fig. 2D), NLRP3 (P = 0.0004, Fig. 2D) level in SH-gfp group, and downregulated GSDME (P = 0.0095, Fig. 2D), IL-18 (P = 0.0354, Fig. 2D) in PD neuron models at different levels.